BioMaxima Statistics

Total Valuation

BioMaxima has a market cap or net worth of PLN 57.66 million. The enterprise value is 72.60 million.

Market Cap	57.66M
Enterprise Value	72.60M

Important Dates

The last earnings date was Tuesday, June 3, 2025.

Earnings Date	Jun 3, 2025
Ex-Dividend Date	n/a

Share Statistics

BioMaxima has 4.19 million shares outstanding. The number of shares has decreased by -1.92% in one year.

Current Share Class	4.19M
Shares Outstanding	4.19M
Shares Change (YoY)	-1.92%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	22.38%
Owned by Institutions (%)	n/a
Float	2.69M

Valuation Ratios

The trailing PE ratio is 65.97.

PE Ratio	65.97
Forward PE	n/a
PS Ratio	1.02
PB Ratio	1.21
P/TBV Ratio	1.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.68, with an EV/FCF ratio of -24.38.

EV / Earnings	83.06
EV / Sales	1.28
EV / EBITDA	13.68
EV / EBIT	37.77
EV / FCF	-24.38

Financial Position

The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.32.

Current Ratio	1.44
Quick Ratio	0.74
Debt / Equity	0.32
Debt / EBITDA	2.93
Debt / FCF	-5.21
Interest Coverage	1.60

Financial Efficiency

Return on equity (ROE) is 1.84% and return on invested capital (ROIC) is 1.95%.

Return on Equity (ROE)	1.84%
Return on Assets (ROA)	1.56%
Return on Invested Capital (ROIC)	1.95%
Return on Capital Employed (ROCE)	3.24%
Revenue Per Employee	449,206
Profits Per Employee	6,937
Employee Count	126
Asset Turnover	0.74
Inventory Turnover	2.23

Taxes

Income Tax	-138,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.49% in the last 52 weeks. The beta is 0.46, so BioMaxima's price volatility has been lower than the market average.

Beta (5Y)	0.46
52-Week Price Change	-9.49%
50-Day Moving Average	13.54
200-Day Moving Average	13.52
Relative Strength Index (RSI)	55.59
Average Volume (20 Days)	11,409

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioMaxima had revenue of PLN 56.60 million and earned 874,000 in profits. Earnings per share was 0.21.

Revenue	56.60M
Gross Profit	26.69M
Operating Income	1.92M
Pretax Income	736,000
Net Income	874,000
EBITDA	5.03M
EBIT	1.92M
Earnings Per Share (EPS)	0.21

Full Income Statement

Balance Sheet

The company has 577,000 in cash and 15.52 million in debt, giving a net cash position of -14.94 million or -3.56 per share.

Cash & Cash Equivalents	577,000
Total Debt	15.52M
Net Cash	-14.94M
Net Cash Per Share	-3.56
Equity (Book Value)	47.82M
Book Value Per Share	11.41
Working Capital	8.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.04 million and capital expenditures -1.94 million, giving a free cash flow of -2.98 million.

Operating Cash Flow	-1.04M
Capital Expenditures	-1.94M
Free Cash Flow	-2.98M
FCF Per Share	-0.71

Full Cash Flow Statement

Margins

Gross margin is 47.16%, with operating and profit margins of 3.40% and 1.54%.

Gross Margin	47.16%
Operating Margin	3.40%
Pretax Margin	1.30%
Profit Margin	1.54%
EBITDA Margin	8.88%
EBIT Margin	3.40%
FCF Margin	n/a

Dividends & Yields

BioMaxima does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.92%
Shareholder Yield	n/a
Earnings Yield	1.52%
FCF Yield	-5.17%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioMaxima has an Altman Z-Score of 2.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.67
Piotroski F-Score	4